Phase
Condition
Prostate Cancer
Urologic Cancer
Prostate Cancer, Early, Recurrent
Treatment
N/AClinical Study ID
Ages > 18 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Written informed consent obtained prior to any study-related procedure being performed
Previous, uninterrupted enrollment and treatment in trial number CHL-AA-201.
Exclusion
Exclusion Criteria:
Progressive disease as ascertained by the investigator using standard-of-careevaluations.
CHL-AA-201 D84 blood counts of the following:
Absolute neutrophil count > 1500/µL
Platelets > 100,000/µL
Hemoglobin > 9 g/dL
CHL-AA-201 D84 chemistry values of the following:
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x UpperLimit of Normal (ULN)
Total bilirubin < 1.5 x ULN
Creatinine< 1.5 x ULN
Albumin > 3.0 g/dL
Potassium > 3.5 mmol/L
Study Design
Study Description
Connect with a study center
GU Research Network/Wichita Urology Group
Wichita, Kansas 67226
United StatesSite Not Available
GU Research Network/Urology PC
Lincoln, Nebraska 68516
United StatesSite Not Available
GU Research Network/Urology Cancer Center
Omaha, Nebraska 68130
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.